Aureus gets first customer for discovery Web portal

Swiss-German company Origenis becomes first customer of AurWEB, which offers ser¬vices in drug design, synthesis and characterization.

Register for free to listen to this article
Listen with Speechify
PARIS—After announcing the launch of its AurWEB por­tal in mid-March, Aureus Pharma, a provider of knowl­edge management solutions to accelerate discovery in the life sciences industry, has its first customer subscription to the service, in the form of Swiss-German company Origenis, which offers ser­vices in drug design, synthe­sis and characterization.
AurWEB is a Web portal designed to enable access to all of Aureus Pharma's knowledge databases and analysis applications.
Available on a subscrip­tion basis, the portal offers customers flexible usage of Aureus' comprehen­sive knowledge databases and "brings the power of Aureus Pharma solutions to a wider community of life science researchers," says Dr. André Michel, CEO of Aureus Pharma. Databases accessible through AurWEB include AurSCOPE GPCR, Ion Channel, Kinase, ADME/Drug-Drug Interactions and hERG.
"AurWEB represents a valuable, exemplary data source," says Dr. Michael Thormann, managing director of Origenis GmbH. "We use AurWEB to turn highly relevant knowledge into powerful models for our tech­nology platform. This accelerates our drug discovery projects and improves the quality of the result­ing compounds."
AurWEB's flexible access to biological and chemical activ­ity data for important drug target families will complement Origenis approach to discover novel target-focused drug candidates, Aureus' Michel predicts—something he expects more companies to tap into as well—in areas ranging from chemistry work to biology to pro­teomics.
"While there is a vast amount of data available in the scientific literature, there is no easy way to optimally exploit this data and use this as a source of knowledge and innovation to accelerate the drug discovery process," Michel says. "Our goal is to provide scientists and executives in drug discovery with extensive validated datasets from the literature. To accomplish this, the data has to be structured with high-quality standards and cutting-edge technology and also be compatible with the systems already in use for internal data storage and management in the pharmaceutical industry."

Subscribe to Newsletter
Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

DDN July 2024 Magazine Issue

Latest Issue  

• Volume 20 • Issue 4 • July 2024

July 2024

July 2024 Issue